Drug profile · INN
lanreotide
MYTOLAC
lanreotide (MYTOLAC) is a somatostatin receptor 2 agonist. Associated with Amdipharm Mercury (Australia) Pty Limited.
TGA: approved NMPA: clinical trials
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — lanreotide
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.81
Quick answer
lanreotide (MYTOLAC) is a somatostatin receptor 2 agonist. Associated with Amdipharm Mercury (Australia) Pty Limited.
Key facts
INN lanreotide
Brand MYTOLAC
Mechanism Somatostatin receptor 2 agonist
Originator Amdipharm Mercury (Australia) Pty Limited
Mechanism of action
Somatostatin receptor 2 agonist
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Frequently asked questions
What is lanreotide?
lanreotide (MYTOLAC) is a somatostatin receptor 2 agonist. Associated with Amdipharm Mercury (Australia) Pty Limited.
What is the brand name for lanreotide?
MYTOLAC is a marketed brand name for lanreotide. Check FDA Drugs@FDA for the current US label holder and prescribing information.